Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:chemicalClass |
lysergamide
|
| gptkbp:effect |
psychedelic
|
| gptkbp:firstReported |
2020s
|
| gptkbp:hasMolecularFormula |
C21H27N3O
|
| gptkbp:IUPACName |
(6aR,9R)-N-methyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
|
| gptkbp:legalStatus |
unscheduled
|
| gptkbp:relatedTo |
gptkb:LSD
1P-LSD |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:bfsParent |
gptkb:NLSD_with_myopathy
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
NLSD-M
|